(2R)-2-methyl-4-methylsulfonylmorpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (2R)-2-methyl-4-methylsulfonylmorpholine
• 化学式: C₆H₁₃NO₃S
• 分子量: 179.24
• InChiKey: DOYFEASBIZIJPT-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR<br/>[FR] INHIBITEUR DE BCL-2 SÉLECTIF À BASE DE SULFONAMIDE DISUBSTITUÉ CONTENANT DU MÉTHYLE ET DU TRIFLUOROMÉTHYLE<br/>[ZH] 包括甲基和三氟甲基的双取代磺酰胺类选择性BCL-2抑制剂
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD

  公开号：WO2020238785A1

  公开（公告）日：2020-12-03

  公开包括甲基和三氟甲基的双取代磺酰胺类选择性BCL-2抑制剂，具体公开式I化合物、其立体异构体或其药学上可接受的盐、其制备方法以及包含该化合物的药物组合物。还公开该化合物以及包含该化合物的药物组合物在治疗与抗凋亡蛋白BCL-2相关疾病例如癌症中的用途。
• TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：US20220002290A1

  公开（公告）日：2022-01-06

  Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.
• METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

  公开号：US20220220110A1

  公开（公告）日：2022-07-14

  Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.
• [EN] SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS<br/>[FR] PYRIDOPYRAZINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE SYK
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2014086316A1

  公开（公告）日：2014-06-12

  The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, L, m, p and W are as defined in the specification.